Wire · opportunities
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
Eli Lilly announced successful Phase 3 trial data for retatrutide, its triple-agonist obesity drug, and plans to file for FDA approval in Q1 2027. The drug showed 21-23% body weight loss in patients with diabetes or cardiovascular disease, positioning Lilly as a potential first-mover in the triple-G class.
This Wire brief sits within Fusion42's coverage of Digital Health, and 3 sources have reported it between 23 Jul 2026 and 4 Aug 2026.
◆ ◆ The Wire takeaway
Lilly's triple-G drug will hit the market in 2027 with proven efficacy in diabetic and cardiac patients—segments Novo Nordisk's GLP-1 drugs haven't formally validated. If you're building obesity-adjacent diagnostics, compliance, or patient management tools, you now know which drug class will drive volume and which patient cohorts will adopt first.
◆ Coverage
3 sources · first reported 23 Jul 2026 · latest 4 Aug 2026
◆ Related on Wire
◆ Topics